Regulation of plasma triglycerides in insulin resistance and diabetes.
Level 5 - mechanism / opinion, no new human data
Narrative review describing pathophysiology without systematic review methodology or primary data
PubMed 15925013 · doi:10.1016/j.arcmed.2005.01.005
What was done
This narrative review examines the pathophysiological mechanisms governing hepatic triglyceride regulation, very low density lipoprotein (VLDL) overproduction, and post-transcriptional apolipoprotein B (apoB) processing in insulin resistance and type 2 diabetes mellitus.
What was found
The abstract reports mechanistic pathways and provides no quantitative data or numbers. Hepatic triglyceride accumulation in insulin resistance is driven by three increased sources: uptake of fatty acids from adipose lipolysis, uptake of VLDL and chylomicron remnants, and hepatic de novo lipogenesis. Excess hepatic triglycerides, cholesterol, and active microsomal triglyceride transfer protein protect constitutively synthesized apoB from proteasomal and non-proteasomal degradation, facilitating VLDL assembly and secretion. Subsequent cholesterol ester transfer protein (CETP)-mediated exchange leads to reduced HDL cholesterol, decreased apolipoprotein A-I, and the formation of small, dense, cholesterol-depleted LDL particles.
Why it matters
The paper outlines the metabolic and cellular mechanisms linking insulin resistance to atherogenic dyslipidemia, identifying hepatic lipid synthesis and lipid fractions as targets for cardiovascular risk reduction.
Limits
The abstract contains no primary human data, sample sizes, quantitative effect estimates, or systematic literature search methodology. Claims regarding cardiovascular disease reduction with treatment are stated generally without trial data or comparative figures.
Cited by
- supports Apolipoprotein B (apoB) is constitutively synthesized by the liver under tonic stimulation, and hepatic apoB secretion is primarily regulated through degradation rather than changes in its synthesis rate.